Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Stroke 1Squamous Cell Carcinoma of Head and Neck 1Sleep Initiation and Maintenance Disorders 1Pulmonary Disease, Chronic Obstructive 1Pancreatic Neoplasms 1Oropharyngeal Neoplasms 1Obesity, Abdominal 1Neoplasms 1Mouth Neoplasms 1Lung Neoplasms 1Laryngeal Neoplasms 1Kidney Failure, Chronic 1Hypopharyngeal Neoplasms 1Hematologic Neoplasms 1Head and Neck Carcinoma 1Diabetes Mellitus 1Delirium 1Coronary Artery Disease 1Central Nervous System Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Carcinoma 1COVID-19 1Advanced Breast Adenocarcinoma 1

Interventions

tocilizumab 1Standard of Care 1Specimen Handling 1Practice Guidelines as Topic 1Immunoglobulin G 1Iloprost 1Educational Status 1Disulfides 1Bronchoscopy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Pulmonary Disease, Chronic Obstructive × Practice Guidelines as Topic × Clear all
NCT04361552 2020-06-18

Tocilizumab for the Treatment of Cytokine Release Syndrome in Patients With COVID-19 (SARS-CoV-2 Infection)

Emory University

Phase 3 Withdrawn
Genitourinary

COVID-19, Coronary Artery Disease, Diabetes Mellitus, Kidney Failure, Chronic, Neoplasms, Stroke, Pulmonary Disease, Chronic Obstructive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡